title: [Indications for use of labile blood products and the physiology of blood transfusion in medicine. The French Agency for the Health Safety of Health Products].
abstract: This article presents the French national recommendations for the use of blood products in medicine.
authors.affiliation: Unité de sécurité transfusionnelle et d'hémovigilance, CHU de Rennes, Pontchaillou, France. herve.gouezec@chu-rennes.fr
authors.forename: H
authors.initials: H
authors.lastname: Gouëzec
authors.forename: P
authors.initials: P
authors.lastname: Jego
authors.forename: Pierre
authors.initials: P
authors.lastname: Bétrémieux
authors.forename: Stanislas
authors.initials: S
authors.lastname: Nimubona
authors.forename: Isabelle
authors.initials: I
authors.lastname: Grulois
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D016913:Blood Component Transfusion; D001789:Blood Group Antigens / Q000276:immunology; D001787:Blood Group Incompatibility; D001803:Blood Transfusion; D001810:Blood Volume; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D020896:Hypovolemia / Q000628:therapy; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged
chemical_list: D001688:Biological Products; D001789:Blood Group Antigens